drugset / Trial / NCT01267201

A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form

NCT01267201

Phase 1 Completed 24 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.

Timeline

Start
2010-11
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 32 mg Oral

Indications

No indication recorded.